Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-25-002804
Filing Date
2025-08-12
Accepted
2025-08-12 16:06:58
Documents
62
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q zk2533520.htm   iXBRL 10-Q 1766268
2 EXHIBIT 31.1 exhibit_31-1.htm EX-31.1 13080
3 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 13278
4 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 6187
5 EXHIBIT 32.2 exhibit_32-2.htm EX-32.2 6207
  Complete submission text file 0001178913-25-002804.txt   8065668

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE slxn-20250630.xsd EX-101.SCH 118931
7 XBRL CALCULATION FILE slxn-20250630_cal.xml EX-101.CAL 30443
8 XBRL DEFINITION FILE slxn-20250630_def.xml EX-101.DEF 249898
9 XBRL LABEL FILE slxn-20250630_lab.xml EX-101.LAB 1321621
10 XBRL PRESENTATION FILE slxn-20250630_pre.xml EX-101.PRE 336838
65 EXTRACTED XBRL INSTANCE DOCUMENT zk2533520_htm.xml XML 1160012
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42253 | Film No.: 251206666
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)